Latest Myasthenia Gravis Disease Companies Updates:
UCB Pharma Submitted a New Drug Application (NDA) for rozanolixizumab, a novel investigational drug targeting complement C5, for the treatment of generalized Myasthenia Gravis (gMG). Approval would expand their portfolio of MG therapies alongside zilucoplan, also awaiting FDA decision.
Argenx Announced positive top-line results from Phase 3 MAINSPRING study, confirming the long-term efficacy and safety of Vyvgart (efgartigimod alfa-fcab) for treating adults with gMG. This reinforces its established position in the market.
Catalyst Pharmaceuticals Received FDA Fast Track designation for Firdapse® (amifampridine phosphate) extended-release tablets for treating Lambert-Eaton myasthenic syndrome (LEMS), offering a potential new option for this rare neuromuscular disorder.
Alexion Pharmaceuticals: Acquired AstraZeneca's rare disease portfolio, including Ultomiris®, a long-acting complement C5 inhibitor approved for treating MG, strengthening their presence in the market.
Mitsubishi Tanabe Pharma Corporation Partnered with Kyowa Hakko Bio Co., Ltd. to develop and commercialize novel oral therapies for MG, leveraging their combined expertise in drug discovery and development.
Myasthenia Gravis Foundation of America (MGFA) Collaborated with pharmaceutical companies and research institutions to fund clinical trials and support research initiatives advancing MG treatment and management.
List of Myasthenia Gravis Disease Key companies in the market:
- Apollo Endosurgery Inc.
- Johnson & Johnson Services Inc.
- Olympus Corporation
- ALLERGAN
- TransEnterix Surgical, Inc.
- Cousin Biotech
- EndoGastric Solutions, Inc.
- ReShape Lifesciences, Inc.
- Medtronic
